United States Inflammatory Bowel Disease Market is expected to reach US$ 36.27 Billion by 2033 | Major key players - AbbVie Inc, Pfizer Inc, Biogen.

Market Size and Growth:

The Global Inflammatory Bowel Disease Market size reached US$ 22.48 Billion in 2024 and is expected to reach US$ 36.27 Billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033. The Market is driven by rising disease prevalence, increasing adoption of biologics and targeted therapies, and ongoing advancements in treatment options. According to DataM Intelligence

To Download a Free Sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/inflammatory-bowel-disease-market?sz

The Inflammatory Bowel Disease (IBD) Market encompasses products and therapies aimed at diagnosing, managing, and treating chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis. It includes pharmaceuticals, biologics, biosimilars, and advanced therapies focused on reducing inflammation, improving patient quality of life, and preventing disease relapse and complications.

Industry Recent Developments:

United States:

✅ September 2025: The FDA accepted Takeda's biologics license application for the subcutaneous administration of ENTYVIO (vedolizumab) for Crohn's disease treatment, paving the way for new biologics and treatment options in the US IBD market.

✅ August 2025: The USA continues to see growth with biologic drugs like Stekinumab (IL-12 and IL-23 inhibitor) being approved for Crohn's disease treatment, expanding targeted treatment options.

✅ July 2025: Hackensack University Medical Center inaugurated a dedicated Center for Inflammatory Bowel Disease, offering specialized care to IBD patients and boosting advanced treatment access.

Japan:

✅ October 2025: The Japan IBD drugs market is projected to grow with innovative biologics and targeted therapies providing improved efficacy and safety, driven by rising IBD incidence and advancements in pharmaceutical research.

✅ September 2025: Personalized medicine approaches in Japan are increasingly adopted in IBD treatment, using genetic and biomarker diagnostics to tailor therapies and improve patient outcomes.

✅ August 2025: Expansion of telemedicine and digital health platforms in Japan is enhancing patient access to IBD care and management, supported by government policies and investment in R&D for novel therapeutics.

Get Customization in the report as per your requirements + Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/inflammatory-bowel-disease-market?sz

Key FDA Approvals (2025):

✅ Mirikizumab (Omvoh) - FDA approval for Crohn's disease (Jan 15, 2025). Lilly's mirikizumab, previously approved for ulcerative colitis, gained approval for moderately to severely active Crohn's disease, widening its IBD label.

✅ Guselkumab (TREMFYA) - FDA approval for Crohn's disease (Mar 20, 2025). Janssen/Johnson & Johnson's TREMFYA became an FDA-approved IL-23 option for adults with moderately-to-severely active Crohn's disease (adds a subcutaneous/induction regimen option).

Major Regulatory Approvals / EU actions (2025):

✅ European Commission approval - TREMFYA (guselkumab) for ulcerative colitis (April 25, 2025). EC expanded TREMFYA's UC indication in 2025 (subcutaneous induction → maintenance).

Notable Mergers & Acquisitions impacting IBD R&D (2025):

✅ Eli Lilly / Morphic (transaction completed 2024; integration & program activity carried into 2025). Lilly's acquisition of Morphic (oral α4β7 integrin program MORF-057) remains a key IBD strategic move that shaped 2025 pipelines and portfolio positioning.

✅ Eli Lilly - acquisition of Organovo's FXR program (announced Feb 25, 2025). Lilly picked up Organovo's FXR program (FXR314), strengthening small-molecule approaches relevant to gut/immunometabolic biology and IBD-adjacent research.

Major Key Players:

AbbVie Inc
Takeda Pharmaceutical Company Limited
Pfizer Inc
Biogen
Johnson & Johnson
Bristol-Myers Squibb Company
EA Pharma Co., Ltd
Salix Pharmaceuticals.

Segments Covered in the Inflammatory Bowel Disease Market:

By Type: Crohn's Disease, Ulcerative colitis.

By Drug Type: Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Biologics, Others.

By Route of Administration: Oral, Rectal, Subcutaneous, Intravenous.

Regional Analysis for Inflammatory Bowel Disease Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=inflammatory-bowel-disease-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Inflammatory Bowel Disease market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Inflammatory Bowel Disease Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Inflammatory Bowel Disease market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Inflammatory Bowel Disease Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Inflammatory Bowel Disease market?

➠ Who are the global key manufacturers of the Inflammatory Bowel Disease Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Inflammatory Bowel Disease market opportunities and threats faced by the vendors in the global Inflammatory Bowel Disease Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Inflammatory Bowel Disease market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.